{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:36:39Z","timestamp":1791221799164,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00210-025-03911-8","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:55:55Z","timestamp":1740383755000},"page":"10429-10443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence-based investigation of the efficacy and safety of venetoclax-containing regimens versus chemoimmunotherapy in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"398","author":[{"given":"Pu","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"3911_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.jval.2022.04.001","volume":"25","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I (2022) Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia. Value in Health 25:1685\u20131695","journal-title":"Value in Health"},{"key":"3911_CR2","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A-M, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le D\u00fb K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner C-M, Kreuzer K-A, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K (2020) Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 21:1188\u20131200","journal-title":"Lancet Oncol"},{"key":"3911_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/ajh.26260","volume":"96","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B, Hallek M, Fischer K (2021) Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: results from the randomized, phase 3 CLL14 trial. Am J Hematol 96:1112\u20131119","journal-title":"Am J Hematol"},{"key":"3911_CR4","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink AM, Tausch E, Schneider C, Ritgen M, Bottcher S, Kreuzer KA, Chyla B, Miles D, Wendtner CM, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K (2021) Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol Off J Am Soc Clin Oncol 39:4049\u20134060","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3911_CR5","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K (2023) Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun 14:2147","journal-title":"Nat Commun"},{"key":"3911_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","volume":"19","author":"P Cramer","year":"2018","unstructured":"Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink A-M, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer K-A, B\u00f6ttcher S, Ritgen M, Kneba M, Wendtner C-M, Stilgenbauer S, Eichhorst B, Hallek M (2018) Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:1215\u20131228","journal-title":"Lancet Oncol"},{"key":"3911_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","volume":"22","author":"MS Davids","year":"2021","unstructured":"Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR (2021) Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol 22:1391\u20131402","journal-title":"Lancet Oncol"},{"key":"3911_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood.2021011386","volume":"139","author":"MS Davids","year":"2022","unstructured":"Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR (2022) Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood 139:686\u2013689","journal-title":"Blood"},{"key":"3911_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann C, Kater A, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U (2021) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol 32:23\u201333","journal-title":"Annals Oncol"},{"key":"3911_CR10","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"Eichhorst B, Niemann CU, Kater AP, Furstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schottker B, Nosslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jager U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Bruggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M, Gcllsg tH, Nordic Cll Study Groups tStICLLA, Cancer Trials I","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, Furstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schottker B, Nosslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jager U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Bruggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M, Gcllsg tH, Nordic Cll Study Groups tStICLLA, Cancer Trials I (2023) First-line venetoclax combinations in chronic lymphocytic leukemia. The New England Med 388:1739\u20131754","journal-title":"The New England Med"},{"key":"3911_CR11","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le D\u00fb K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner C-M, Langerak AW, Kreuzer K-A, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. New England J Med 380:2225\u20132236","journal-title":"New England J Med"},{"key":"3911_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"M Furstenau","year":"2024","unstructured":"Furstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstrom V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nosslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Durig J, Stehle A, Vohringer M, Bottcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Bruggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B (2024) First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 25:744\u2013759","journal-title":"Lancet Oncol"},{"key":"3911_CR13","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"M Hallek","year":"2019","unstructured":"Hallek M (2019) Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 94:1266\u20131287","journal-title":"Am J Hematol"},{"key":"3911_CR14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, Munoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T (2019) Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol Off J Am Soc Clin Oncol 37:2722\u20132729","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3911_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2021013208","volume":"139","author":"H Huber","year":"2022","unstructured":"Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Furstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Durig J, Bottcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Dohner H, Hallek M, Eichhorst B, Stilgenbauer S (2022) Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood 139:1318\u20131329","journal-title":"Blood"},{"key":"3911_CR16","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W (2019) Ibrutinib and venetoclax for first-line treatment of CLL. The New England J Med 380:2095\u20132103","journal-title":"The New England J Med"},{"key":"3911_CR17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","volume":"7","author":"N Jain","year":"2021","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG (2021) Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol 7:1213\u20131219","journal-title":"JAMA Oncol"},{"key":"3911_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ (2019) Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol Off J Am Soc Clin Oncol 37:269\u2013277","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3911_CR19","doi-asserted-by":"crossref","unstructured":"Kater AP, Levin M-D, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, van der Kevie-Kersemaekers A-MF, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schj\u00f8dt I, Dompeling EC, Ranti J, Brieghel C, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Niemann CU (2022a) Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 23:818\u2013828","DOI":"10.1016\/S1470-2045(22)00220-0"},{"key":"3911_CR20","doi-asserted-by":"crossref","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin MD, Benjamini O, Janssens A, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Ysebaert L, Qin R, Steele AJ, Schuier N, Baeten K, Caces DB, Niemann CU (2022b) Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM evidence 1: EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006"},{"key":"3911_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","volume":"25","author":"AP Kater","year":"2024","unstructured":"Kater AP, Arslan O, Demirkan F, Herishanu Y, Ferhanoglu B, Diaz MG, Leber B, Montillo M, Panayiotidis P, Rossi D, Skarbnik A, Tempescul A, Turgut M, Mellink CH, van der Kevie-Kersemaekers AF, Lanham S, Sale B, Del Rio L, Popovic R, Chyla BJ, Busman T, Komlosi V, Wang X, Sail K, Pena GE, Vizkelety T, Forconi F (2024) Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. Lancet Oncol 25:463\u2013473","journal-title":"Lancet Oncol"},{"key":"3911_CR22","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","volume":"9","author":"S Kersting","year":"2022","unstructured":"Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP, group HCs, (2022) Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Hematol 9:e190\u2013e199","journal-title":"Lancet Hematol"},{"key":"3911_CR23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood.2020009578","volume":"138","author":"S Ma","year":"2021","unstructured":"Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, Humphrey K, Al Masud A, Pesko J, Nandam R, Salem AH, Chyla B, Arzt J, Jacobson A, Kim SY, Roberts AW (2021) Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood 138:836\u2013846","journal-title":"Blood"},{"key":"3911_CR24","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3324\/haematol.2022.282116","volume":"108","author":"FR Mauro","year":"2023","unstructured":"Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarf\u00f2 L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Fo\u00e0 R (2023) High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 \u2013 VERITAS study. Haematologica 108:2091\u20132100","journal-title":"Haematologica"},{"key":"3911_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P, National Cancer Research Institute Chronic Lymphocytic Leukemia S","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P, National Cancer Research Institute Chronic Lymphocytic Leukemia S (2024) Chronic lymphocytic leukemia therapy guided by measurable residual disease. The New England J Med 390:326\u2013337","journal-title":"The New England J Med"},{"key":"3911_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP (2023) Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24:1423\u20131433","journal-title":"Lancet Oncol"},{"key":"3911_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3911_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/bloodadvances.2023011964","volume":"8","author":"C Prosty","year":"2024","unstructured":"Prosty C, Katergi K, Nguyen A, Luo OD, Sorin M, Cherniak V, Sebag M, Demir K, McDonald EG, Lee TC, Cheng MP (2024) Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs. Blood Adv 8:857\u2013866","journal-title":"Blood Adv"},{"key":"3911_CR29","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00277-024-05638-7","volume":"103","author":"I Schwaner","year":"2024","unstructured":"Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, H\u00fclsenbeck J, Famulla K, N\u00f6sslinger T, Rossi D (2024) Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Annals Hematol 103:2013\u20132020","journal-title":"Annals Hematol"},{"key":"3911_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP (2018) Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New England J Med 378:1107\u20131120","journal-title":"New England J Med"},{"key":"3911_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, D\u2019Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP (2022) Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140:839\u2013850","journal-title":"Blood"},{"key":"3911_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M (2023) Diagnosis and treatment of chronic lymphocytic leukemia: a review. Jama 329:918\u2013932","journal-title":"Jama"},{"key":"3911_CR33","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","volume":"8","author":"JD Soumerai","year":"2021","unstructured":"Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD (2021) Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Hematol 8:e879\u2013e890","journal-title":"Lancet Hematol"},{"key":"3911_CR34","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj 366:l4898","journal-title":"Bmj"},{"key":"3911_CR35","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Bottcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG (2018) Venetoclax for patients with chronic lymphocytic leukemia with 17p DELETION: results from the full population of a phase II pivotal trial. J Clin Oncol Off J Am Soc Clin Oncol 36:1973\u20131980","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3911_CR36","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1182\/bloodadvances.2023011741","volume":"8","author":"S Stilgenbauer","year":"2024","unstructured":"Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Bottcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF (2024) Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv 8:1992\u20132004","journal-title":"Blood Adv"},{"key":"3911_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10238-021-00739-3","volume":"22","author":"X Tang","year":"2021","unstructured":"Tang X, Zou W, Peng P, Bai Y (2021) Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed\/refractory chronic lymphocytic leukemia: a meta-analysis. Clin Exp Med 22:161\u2013171","journal-title":"Clin Exp Med"},{"key":"3911_CR38","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood.2019004492","volume":"135","author":"E Tausch","year":"2020","unstructured":"Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink A-M, Eichhorst B, Kreuzer K-A, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Lur\u00e0 MP, Kneba M, D\u00f6hner H, Fischer K, Hallek M, Stilgenbauer S (2020) Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood 135:2402\u20132412","journal-title":"Blood"},{"key":"3911_CR39","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1182\/bloodadvances.2024013927","volume":"8","author":"YK Valtis","year":"2024","unstructured":"Valtis YK, Nemirovsky D, Derkach A, Sharan S, Kabel C, Ortiz R, Thompson MC, Roeker LE, Geyer MB (2024) Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax. Blood Adv 8:5806\u20135813","journal-title":"Blood Adv"},{"key":"3911_CR40","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS (2021) Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol Off J Am Soc Clin Oncol 39:3853\u20133865","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03911-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03911-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03911-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:21:38Z","timestamp":1757139698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03911-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3911"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03911-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}